Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Dec;88(6):1062-1064.
doi: 10.1002/ana.25907. Epub 2020 Sep 30.

Multiple Sclerosis Disease-Modifying Therapies in the COVID-19 Era

John R Ciotti  1 , Elena Grebenciucova  2 , Brandon P Moss  3 , Scott D Newsome  4
Affiliations

Multiple Sclerosis Disease-Modifying Therapies in the COVID-19 Era

John R Ciotti et al. Ann Neurol. 2020 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

J.R.C.: funded by a Sylvia Lawry Physician Fellowship grant, the National Multiple Sclerosis Society; E.G.: nothing to report; B.P.M.: research funding for investigator‐initiated studies, Roche; site Principal Investigator for studies sponsored by Roche; speaking fees, Genzyme; consulting fees, Roche; owns stock, Pfizer; S.D.N.: scientific advisory boards, Biogen, Genentech, Celgene, Novartis, Greenwich Biosciences, EMD Serono; clinical trial clinical adjudication committee member, BioIncept, Autobahn Therapeutics, medDay Pharmaceuticals; grant/research funding (paid directly to institution), Biogen, Genentech, National Multiple Sclerosis Society, Department of Defense, and Patient Centered Outcomes Institute.

References

    1. COViMS Registry . The COViMS Database Public Data Update. www.COViMS.org. Accessed September 1, 2020.
    1. Louapre C, Collongues N, Stankoff B, et al. Clinical characteristics and outcomes in patients with coronavirus disease 2019 and multiple sclerosis. JAMA Neurol 2020;77:e202581. - PMC - PubMed
    1. Sormani MP. Italian study group on COVID‐19 infection in multiple sclerosis. An Italian programme for COVID‐19 infection in multiple sclerosis. Lancet Neurol 2020;19:481–482. - PMC - PubMed
    1. Moss BP, Mahajan KR, Bermel RA, et al. Multiple sclerosis management during the COVID‐19 pandemic. Mult Scler 2020;26:1352458520948231. - PMC - PubMed
    1. Bar‐Or A, Calkwood JC, Chognot C, et al. Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: the VELOCE study. Neurology 2020;10.1212/WNL.0000000000010380. - PMC - PubMed

MeSH terms

Substances